Abstract
Tolvaptan introduction has constituted the main therapeutic novelty in the management of hyponatremia in recent years. To describe the experience with this drug at Complejo Asistencial Universitario de León, Spain. Retrospective, observational study of tolvaptan outpatient use in a tertiary care hospital from March 2014 to August 2017. A total of 9 patients were treated with tolvaptan in the outpatient setting. Eunatremia was reached in 24 h by 23.1%. After tolvaptan administration, a reduction in days of hospitalization was recorded (361 vs. 70; p = 0.007), especially in those days of hospitalization that were attributable to hyponatremia (306 vs. 49; p = 0.009). Long-term use of tolvaptan appears to be safe and is associated with a decrease in days of hospitalization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
